OC-048 Filgotinib, a selective jak1 inhibitor, induces clinical remission and a reduction in pstat3 levels in patients with active crohn’s disease: results from the phase ii fitzroy study
OC-048 Filgotinib, a selective jak1 inhibitor, induces clinical remission and a reduction in pstat3 levels in patients with active crohn’s disease: results from the phase ii fitzroy study